Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

Mutations in the gene encoding epidermal growth factor receptor (EGFR) family member HER2 (ERBB2) are common in and drive the growth of “HER2-negative” (not ERBB2-amplified) solid tumors but are rare in primary “HER2-positive” (ERBB2-amplified) breast cancer. We analyzed DNA sequencing data from HER...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Signal
Asıl Yazarlar: Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498841/
https://ncbi.nlm.nih.gov/pubmed/30301790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scisignal.aat9773
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller